Clinical Trials
92 trialsNCT07321912 2026-05-26
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT00077285 2026-05-22
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07049848 2026-05-22
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT01871766 2026-04-24
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT07243626 2026-04-24
Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT04968106 2026-04-21
TORNADO
Institut Bergonié
Phase 2 Active not recruiting
NCT04028063 2026-04-20
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Phase 2 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07125183 2026-02-05
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
Phase 2 Recruiting
NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT06835049 2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2 Recruiting
NCT07231250 2025-11-19
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04776525 2025-08-14
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Oslo University Hospital
Phase 2 Recruiting
NCT04874311 2025-08-13
TRUST
Institut Bergonié
Phase 2 Recruiting
NCT06277154 2025-07-24
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase 2 Recruiting
NCT07034508 2025-06-24
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT03719430 2025-04-29
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Phase 2 Active not recruiting
NCT06524583 2025-03-30
L-UteCIN
UNICANCER
Phase 2 Recruiting
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT06500091 2024-07-15
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Not yet recruiting
NCT04535713 2024-07-05
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT01514188 2024-05-29
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
ImmunityBio, Inc.
Phase 2 Completed
NCT01459484 2024-05-20
ISG/OS-2
Italian Sarcoma Group
Phase 2 Completed
NCT03056001 2023-11-18
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT02584309 2023-11-07
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT03420014 2023-10-10
FIBROSARC US
Philogen S.p.A.
Phase 2 Unknown
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT00667342 2023-08-07
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT03317457 2023-06-15
MEDISARC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT02727387 2022-09-19
EW-2
Italian Sarcoma Group
Phase 2 Completed
NCT04012827 2022-09-07
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT05138146 2021-11-30
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT00000996 2021-11-04
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT04910126 2021-06-02
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT02448537 2021-03-03
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT03698227 2020-07-15
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Terminated
NCT04356872 2020-07-14
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Fudan University
Phase 2 Unknown
NCT00038142 2020-01-29
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00061893 2019-02-15
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT02255110 2018-12-14
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Merck KGaA, Darmstadt, Germany
Phase 2 Terminated
NCT00304083 2018-09-18
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00484341 2018-08-29
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
AGC Biologics S.p.A.
Phase 2 Completed
NCT00089544 2018-04-13
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01313884 2017-11-24
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Stanford University
Phase 2 Terminated
NCT01055314 2017-08-29
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed